Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia

Eek, Daniel; Ivanescu, Cristina; Corredoira, L.; Meyers, Oren; Cella, David

doi:10.1186/s41687-021-00294-1

Cited by 21 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An assessment of structural validity using confirmatory factor analysis (CFA) supported the unidimensionality of the FACIT-F scale. 33 Construct validity, as assessed through the convergent approach, indicated overall good validity. Known-groups validity was supported by differences between groups based on various baseline factors.…”

Section: Symptom Severitymentioning

confidence: 98%

“…One study, which assessed the content validity of the FACIT-F scale in 40 patients in the first line or relapsed or refractory chronic lymphocytic leukemia (CLL) setting in the US, found that interviewed patients understood the terminology and agreed with response options. 33 The same study investigated structural validity, construct validity, known-groups validity, and internal consistency using data from a phase III RCT (ASCEND) 34 in 263 patients with relapsed or refractory CLL. An assessment of structural validity using confirmatory factor analysis (CFA) supported the unidimensionality of the FACIT-F scale.…”

Section: Symptom Severitymentioning

confidence: 99%

“…The FACIT-F total, symptom, and impact subscales demonstrated good internal consistency. 33 No relevant studies were found to assess responsiveness. An MID was not identified in the literature in patients with AML.…”

Section: Symptom Severitymentioning

confidence: 99%

“…One recent study assessed the psychometric properties of the FACIT-F in patients with CLL. 33 Content validity was evaluated using cognitive debriefing (qualitative) interviews conducted with 40 patients with CLL in the first-line or relapsed or refractory setting (self-reported ECOG PS score ≤ 2).…”

Section: Validitymentioning

confidence: 99%

“…Interviewed patients considered the FACIT-F items reflective of their CLL experience, understood most terminologies well and agreed with response options. 33 Additionally, authors of the above study investigated structural validity, internal consistency, construct and known-groups validity using data from a phase III RCT (ASCEND trial) in 263 patients with relapsed or refractory CLL (who had previously been treated with at least 1 systemic therapy and had an ECOG PS score ≤ 2). Confirmatory factor analysis was employed to evaluate the latent structure (i.e., underlying subscales) of the FACIT-F instrument.…”

Section: Validitymentioning

confidence: 99%

See 4 more Smart Citations

Azacitidine (Onureg)

Team¹

2022

cjht

View full text Add to dashboard Cite

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses azacitidine (Onureg), tablet 300 mg, oral. Indication: Maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation.

show abstract

Section: Symptom Severitymentioning

confidence: 98%

Section: Symptom Severitymentioning

confidence: 99%

Section: Symptom Severitymentioning

confidence: 99%

Section: Validitymentioning

confidence: 99%

Section: Validitymentioning

confidence: 99%

See 3 more Smart Citations

Azacitidine (Onureg)

Team¹

2022

cjht

View full text Add to dashboard Cite

show abstract

Fatigue, quality of life and associations with adherence to the World Cancer Research Fund guidelines for health behaviours in 5835 adults living with and beyond breast, prostate and colorectal cancer in England: A cross‐sectional study

et al. 2023

View full text Add to dashboard Cite

Background Many individuals living with and beyond cancer (LWBC) have ongoing quality of life (QoL) issues, including fatigue. The World Cancer Research Fund (WCRF) provides health behaviour recommendations for people LWBC, and there is some evidence linking adherence to these with improved QoL. Methods Adults LWBC (specifically breast, colorectal or prostate cancer) completed a survey covering health behaviours (diet, physical activity, alcohol consumption and smoking), fatigue (FACIT‐Fatigue Scale, version 4) and a broad measure of QoL (EQ‐5D‐5L descriptive scale). Participants were categorised as meeting/not meeting WCRF recommendations, using the following cut‐offs classified as meeting the guidelines: ≥150 min physical activity/week, fruit and vegetables (≥5 portions/day), fibre (≥30 g fibre per day), free sugar (<5% of total calories from free sugar), fat (<33% total energy), red meat (<500 g/week), processed meat (none), alcohol consumption (<14 units/week) and not a current smoker. Logistic regression analyses explored associations between WCRF adherence and fatigue and QoL issues, controlling for demographic and clinical variables. Results Among 5835 individuals LWBC (mean age: 67 years, 56% female, 90% white, breast 48%, prostate 32% and colorectal 21%), 22% had severe fatigue and 72% had 1+ issue/s on the EQ‐5D‐5L. Adhering to physical activity recommendations (odds ratio [OR] = 0.88, confidence interval [CI] = 0.77–0.99), meeting various dietary recommendations (fruit and vegetables OR = 0.79; CI = 0.68–0.91, free sugar OR = 0.85; CI = 0.76–0.96, fat OR = 0.71; CI = 0.62–0.82, red meat OR = 0.65; CI = 0.50–0.85) and not smoking (OR = 0.53, CI = 0.41–0.67) were associated with decreased odds of experiencing severe fatigue. Adhering to physical activity guidelines (OR = 0.71, CI = 0.62–0.82) was also associated with decreased odds of having 1+ QoL issue/s. Conclusions Adherence to various WCRF recommendations, particularly the recommendation for physical activity, was associated with less fatigue and better QoL in a large UK cohort of people living with and beyond breast, colorectal or prostate cancer. Multi‐component interventions designed to support people LWBC to improve health behaviours, in line with the levels recommended by the WCRF, may also improve QoL.

show abstract

Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms

et al. 2022

View full text Add to dashboard Cite

Background Myeloproliferative neoplasms (MPNs) are rare haematological cancers. Several studies report the most common MPN symptom leading to reduced quality of life is fatigue. Yet, how fatigue affects the lives of people with MPN is not well described. Aims The purpose of this qualitative study is to better understand the lived experience of fatigue associated with MPN. Methods and results People with MPN who had experienced fatigue were invited to complete an online survey and if eligible, then to participate in semi‐structured interviews and focus groups, exploring their experiences of fatigue. Thematic analysis of interview transcripts by two researchers produced themes describing the lived experience of fatigue. Twenty‐three people with MPN participated in seven interviews and four focus groups. Qualitative data revealed how fatigue significantly affected participants' experiences of functional, social, family and emotional wellbeing. Participants reported that fatigue was infrequently acknowledged or addressed by health professionals, and a lack of information or support to manage their fatigue. Four themes including 12 sub‐themes describe the experience of fatigue in MPN: (1) the distress of the MPN diagnosis, (2) sensations of fatigue, (3) daily life and emotional burden with fatigue and (4) how people managed their fatigue with limited guidance. Conclusion Fatigue in MPN is common, debilitating and distressing. It affects all aspects of health, wellbeing and life. Health professionals could affect patients' lives substantially by acknowledging and understanding fatigue in MPN, including contributing factors and potential opportunities for management. More systematic data describing the causes and management of MPN fatigue is needed.

show abstract

Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia

Cited by 21 publications

References 32 publications

Azacitidine (Onureg)

Azacitidine (Onureg)

Fatigue, quality of life and associations with adherence to the World Cancer Research Fund guidelines for health behaviours in 5835 adults living with and beyond breast, prostate and colorectal cancer in England: A cross‐sectional study

Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms

Contact Info

Product

Resources

About